Medicare Part D coverage · carbinoxamine maleate · RxCUI 2730039
carbinoxamine maleate 0.8 MG/ML Oral Solution [Carbzah]
Per the CMS 2026 Part D formulary file, carbinoxamine maleate 0.8 MG/ML Oral Solution [Carbzah] is covered by 22 Medicare Part D plans (0.4% of enrollable products), averaging Tier 2.2, with prior authorization required on 50% of covering formularies.
- 0.4%
- Plan coverage
- 22
- Plans covering
- T2.2
- Avg tier
- 50%
- Prior auth required
What the CMS Formulary Data Shows for carbinoxamine maleate 0.8 MG/ML Oral Solution [Carbzah]
Per the CMS 2026 Part D formulary file, carbinoxamine maleate 0.8 MG/ML Oral Solution [Carbzah] (RxNorm concept RXCUI 2730039, generic name carbinoxamine maleate) appears on 6 distinct formulary files spanning 22 Medicare Part D plan offerings - 0.4% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 2.2.
Real-world access to carbinoxamine maleate 0.8 MG/ML Oral Solution [Carbzah] depends on utilization management as much as tier placement: 50% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 1,400 Part D beneficiaries filled carbinoxamine maleate 0.8 MG/ML Oral Solution [Carbzah] in 2023, with total plan-and-beneficiary spending of $921,020 and an average per-beneficiary annual cost of $657.87. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry carbinoxamine maleate 0.8 MG/ML Oral Solution [Carbzah] today.
Coverage Details
- Formularies covering
- 6
- Plans covering
- 22
- Coverage rate
- 0.4%
- Tier range
- Tier 1 – Tier 4
- Average tier
- Tier 2, Generic
Restrictions
- Prior authorization required
- 50% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 1,400
- Total spending
- $921,020
- Avg per beneficiary
- $657.87
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering carbinoxamine maleate 0.8 MG/ML Oral Solution [Carbzah]
22 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| PHP (HMO C-snp) | Aids Healthcare Foundation | T1 | Yes | $0 | CA |
| VNS Health Total (HMO D-SNP) | VNS Choice | T1 | No | $0 | NY |
| Gold Dialysis & Kidney Complete (HMO-POS C-SNP) | Gold Kidney OF Florida Inc | T1 | No | $4.80 | FL |
| Gold Dialysis & Kidney Complete (HMO-POS C-SNP) | Gold Kidney OF Arizona | T1 | No | $17.00 | AZ |
| VNS Health EasyCare Plus (HMO D-SNP) | VNS Choice | T1 | No | $51.60 | NY |
| Gold Heart & Diabetes (HMO-POS C-SNP) | Gold Kidney OF Florida Inc | T2 | No | $0 | FL |
| Gold Heart & Diabetes Complete (HMO-POS C-SNP) | Gold Kidney OF Florida Inc | T2 | No | $0 | FL |
| Gold Dialysis & Kidney (HMO-POS C-SNP) | Gold Kidney OF Florida Inc | T2 | No | $0 | FL |
| Gold Health (HMO-POS C-SNP) | Gold Kidney OF Florida Inc | T2 | No | $0 | FL |
| Gold Dialysis & Kidney (HMO-POS C-SNP) | Gold Kidney OF Florida Inc | T2 | No | $0 | FL |
| Gold Heart & Diabetes (HMO-POS C-SNP) | Gold Kidney OF Arizona | T2 | No | $0 | AZ |
| Gold Dialysis & Kidney (HMO-POS C-SNP) | Gold Kidney OF Arizona | T2 | No | $0 | AZ |
| Gold Heart & Diabetes (HMO-POS C-SNP) | Gold Kidney OF Arizona | T2 | No | $0 | AZ |
| Gold Dialysis & Kidney (HMO-POS C-SNP) | Gold Kidney OF Arizona | T2 | No | $0 | AZ |
| SummaCare Medicare Topaz (HMO) | Summacare Inc. | T4 | Yes | $0 | OH |
| SummaCare Medicare Quartz (HMO) | Summacare Inc. | T4 | Yes | $0 | OH |
| VillageCareMAX Medicare Health Advantage Plan (HMO D-SNP) | Village Senior Services Corporation | T4 | Yes | $0 | NY |
| VillageCareMAX Medicare Total Advantage Plan (HMO D-SNP) | Village Senior Services Corporation | T4 | Yes | $0 | NY |
| SummaCare Medicare Garnet (HMO) | Summacare Inc. | T4 | Yes | $35.00 | OH |
| SummaCare Medicare Ruby (HMO) | Summacare Inc. | T4 | Yes | $50.00 | OH |
Show the next 2 plans
| SummaCare Medicare Sapphire (HMO-POS) | Summacare Inc. | T4 | Yes | $83.00 | OH |
| SummaCare Medicare Emerald (HMO-POS) | Summacare Inc. | T4 | Yes | $100.80 | OH |
Frequently Asked Questions
Is carbinoxamine maleate 0.8 MG/ML Oral Solution [Carbzah] covered by Medicare Part D?
Yes, carbinoxamine maleate 0.8 MG/ML Oral Solution [Carbzah] is covered by 22 Medicare Part D plans (0.4% of all Part D formularies).
What tier is carbinoxamine maleate 0.8 MG/ML Oral Solution [Carbzah] on Medicare Part D plans?
carbinoxamine maleate 0.8 MG/ML Oral Solution [Carbzah] averages Tier 2.2 across Part D plans, ranging from Tier 1 to Tier 4.
Does carbinoxamine maleate 0.8 MG/ML Oral Solution [Carbzah] require prior authorization?
50% of Part D formularies require prior authorization for carbinoxamine maleate 0.8 MG/ML Oral Solution [Carbzah]. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on carbinoxamine maleate 0.8 MG/ML Oral Solution [Carbzah]?
In 2023, total Medicare Part D spending on carbinoxamine maleate 0.8 MG/ML Oral Solution [Carbzah] was $921,020, covering 1,400 beneficiaries. The average spend per beneficiary was $657.87.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
Similar prior-authorization rate
- 0.2 ML adalimumab-atto 50 MG/ML Prefilled Syringe [Amjevita] 50% PA
- prednisolone 15 MG Disintegrating Oral Tablet [Orapred] 50% PA
- trazodone hydrochloride 10 MG/ML Oral Solution [Raldesy] 50% PA
- lactulose 20000 MG Powder for Oral Solution 50% PA
- 168 HR estradiol 0.00104 MG/HR Transdermal System [Climara] 50% PA
- 72 HR fentanyl 0.075 MG/HR Transdermal System 50% PA